Your browser doesn't support javascript.
loading
Retinal stem cell transplantation: Balancing safety and potential.
Singh, Mandeep S; Park, Susanna S; Albini, Thomas A; Canto-Soler, M Valeria; Klassen, Henry; MacLaren, Robert E; Takahashi, Masayo; Nagiel, Aaron; Schwartz, Steven D; Bharti, Kapil.
Afiliación
  • Singh MS; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. Electronic address: mandeep@jhmi.edu.
  • Park SS; Department of Ophthalmology & Vision Science, University of California-Davis Eye Center, Sacramento, CA, 95817, USA.
  • Albini TA; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Canto-Soler MV; CellSight Ocular Stem Cell and Regeneration Research Program, Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
  • Klassen H; Gavin Herbert Eye Institute and Stem Cell Research Center, Irvine, CA, 92697, USA.
  • MacLaren RE; Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford and Oxford University Eye Hospital, NHS Foundation Trust, NIHR Biomedical Research Centre, Oxford, OX3 9DU, UK.
  • Takahashi M; Laboratory for Retinal Regeneration, Center for Biosystems Dynamics Research, RIKEN, Kobe, Hyogo, 650-0047, Japan.
  • Nagiel A; The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, 90027, USA; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90007, USA.
  • Schwartz SD; Stein Eye Institute, University of California Los Angeles Geffen School of Medicine, Los Angeles, CA, 90095, USA; Edythe and Eli Broad Stem Cell Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Bharti K; National Eye Institute, National Institutes of Health, Bethesda, MD, 90892, USA.
Prog Retin Eye Res ; 75: 100779, 2020 03.
Article en En | MEDLINE | ID: mdl-31494256
Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retina / Degeneración Retiniana / Trasplante de Células Madre / Epitelio Pigmentado de la Retina / Células Madre Pluripotentes Inducidas / Tratamiento Basado en Trasplante de Células y Tejidos Límite: Humans Idioma: En Revista: Prog Retin Eye Res Asunto de la revista: OFTALMOLOGIA Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retina / Degeneración Retiniana / Trasplante de Células Madre / Epitelio Pigmentado de la Retina / Células Madre Pluripotentes Inducidas / Tratamiento Basado en Trasplante de Células y Tejidos Límite: Humans Idioma: En Revista: Prog Retin Eye Res Asunto de la revista: OFTALMOLOGIA Año: 2020 Tipo del documento: Article